Natural Hazard and Risk Management for Pipelines

2002 ◽  
Author(s):  
K. Wayne Savigny ◽  
Michael Porter ◽  
Joyce Chen ◽  
Eugene Yaremko ◽  
Michael Reed ◽  
...  
Keyword(s):  
Risk Management ◽  
Natural Hazard ◽  
Standard Of Care ◽  
Hazard Identification ◽  
Ground Movement ◽  
Main Line ◽  
Current Standard ◽  
Pipe Line ◽  
Hazard And Risk ◽  
Risk Management Methodology

Pipeline systems must contend with many hazards, of which ground movements such as landslides and washouts represent one type. Under the broader umbrella term, natural hazards, individual ground movement threats can be subdivided into geotechnical and hydrotechnical hazards. A four-phase natural hazard and risk management system (NHRM) is being developed. Although research and development are ongoing, implementation over the past seven years spans approximately 25,000 km of main-line pipeline in North and South America. It complies with CSA requirements for ‘hazard identification’ as well as current standard-of-care guidelines related to case-law in Canada. It is designed as a simple yet reproducible methodology that can be operated by pipeline companies, particularly their field staff. The first two phases of hazard identification/assessment are described here with reference to a recent study of hydrotechnical hazards along the Trans Mountain Pipe Line Co. Ltd. main line from Hinton, Alberta to Kamloops, British Columbia in the mountains of western Canada. The relative hazard ratings generated by the Phase I and II methodology can be integrated into existing risk management methodologies used in the industry. Alternatively, the risk assessment and risk management methodology of the NHRM system can be used as outlined in this paper.

Natural Hazard and Risk Management for South American Pipelines

2002 ◽  
Author(s):  
Michael Porter ◽  
K. Wayne Savigny
Keyword(s):  
Risk Management ◽  
Volcanic Eruption ◽  
Natural Hazard ◽  
Standard Of Care ◽  
Hazard Identification ◽  
South American ◽  
Hazard Exposure ◽  
Hazard And Risk ◽  
Two Phases ◽  
Design And Construction

Hazard identification and rating involve the first two of a four-phase natural hazard and risk management (NHRM) system that is being developed to manage natural hazards along linear facilities. In Canada, completing these first two phases is generally straightforward. Baseline data including air photos, geology and topographic maps are readily available; the number and types of hazard exposure are often limited for any given facility; and, the standard of care expected during design and construction is understood and practiced. The NHRM methodology is also being applied on South American pipelines. Greater flexibility is required in obtaining necessary input data. Helicopter and vehicle access are often more limited, and greater reliance must be placed on airphoto interpretation and literature review. Processes of rating hazard exposure are needed for less familiar hazard types, including tsunami, volcanic eruption, and tectonic ground rupture. South American construction and design practices must be accounted for in the rating methodology. Using examples from recently constructed trans Andean pipelines, this paper outlines application of the NHRM system to linear facilities located in areas of diverse hazard exposure and less stringent design and construction practices. Under the broad headings of ‘geotechnical’ and ‘hydrotechnical’ hazards, a methodology for rating eleven different hazard types is outlined. On the geotechnical side, these include tsunami, volcanic eruption, tectonic ground rupture, landslides and debris flows originating off-rights-of-way, and mass movements originating on rights-of-way. Hydrotechnical hazards include scour, degradation, bank erosion, encroachment, and channel abandonment/avulsion.

Challenges for Natural Hazard and Risk Management in Mountain Regions of Europe

2018 ◽  
Author(s):  
Margreth Keiler ◽  
Sven Fuchs
Keyword(s):  
Climate Change ◽  
Risk Management ◽  
19Th Century ◽  
Natural Hazard ◽  
Management Strategies ◽  
Risk Governance ◽  
Mountain Regions ◽  
Hazard And Risk ◽  
European Mountain ◽  
Three Components

European mountain regions are diverse, from gently rolling hills to high mountain areas, and from low populated rural areas to urban regions or from communities dependent on agricultural productions to hubs of tourist industry. Communities in European mountain regions are threatened by different hazard types: for example floods, landslides, or glacial hazards, mostly in a multi-hazard environment. Due to climate change and socioeconomic developments they are challenged by emerging and spatially as well as temporally highly dynamic risks. Consequently, over decades societies in European mountain ranges developed different hazard and risk management strategies on a national to local level, which are presented below focusing on the European Alps. Until the late 19th century, the paradigm of hazard protection was related to engineering measures, mostly implemented in the catchments, and new authorities responsible for mitigation were founded. From the 19th century, more integrative strategies became prominent, becoming manifest in the 1960s with land-use management strategies targeted at a separation of hazardous areas and areas used for settlement and economic purpose. In research and in the application, the concept of hazard mitigation was step by step replaced by the concept of risk. The concept of risk includes three components (or drivers), apart from hazard analysis also the assessment and evaluation of exposure and vulnerability; thus, it addresses in the management of risk reduction all three components. These three drivers are all dynamic, while the concept of risk itself is thus far a static approach. The dynamic of risk drivers is a result of both climate change and socioeconomic change, leading through different combinations either to an increase or a decrease in risk. Consequently, natural hazard and risk management, defined since the 21st century using the complexity paradigm, should acknowledge such dynamics. Moreover, researchers from different disciplines as well as practitioners have to meet the challenges of sustainable development in the European mountains. Thus, they should consider the effects of dynamics in risk drivers (e.g., increasing exposure, increasing vulnerability, changes in magnitude, and frequency of hazard events), and possible effects on development areas. These challenges, furthermore, can be better met in the future by concepts of risk governance, including but not limited to improved land management strategies and adaptive risk management.

scholarly journals The APHIRM toolkit: an evidence-based system for workplace MSD risk management

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Jodi Oakman ◽  
Wendy Macdonald
Keyword(s):  
Risk Management ◽  
Occupational Health ◽  
Health And Safety ◽  
Occupational Health And Safety ◽  
Hazard Identification ◽  
Evidence Based ◽  
Risk Levels ◽  
Psychosocial Hazards ◽  
Hazard And Risk ◽  
Management Cycle

Abstract Musculoskeletal disorders (MSDs) continue as one of the largest occupational health and safety problems worldwide. One reason for this situation is that current workplace risk management practices fail to meet some important evidence-based requirements for effective reduction of MSD risk. In particular: they largely fail to address risk arising from psychosocial hazards; do not allow sufficient participation by workers; and often fail to control risk at its sources. To address these deficiencies, A Participative Hazard Identification and Risk Management (APHIRM) toolkit has been formulated in accordance with both a framework developed by the World Health Organisation and implementation science principles. It comprises a set of online tools that include automated data analysis and reporting modules, and procedures to guide users through the five stages of the conventional risk management cycle. Importantly, it assesses both hazard and risk levels for groups of people doing a particular job, focusing on the job overall rather than only on tasks deemed to be hazardous. Its intended users are workplace managers and consultants responsible for occupational health and safety, with active participation from workers also. Resultant risk control interventions are customized to address the main physical and psychosocial hazards identified for the target job, and repetitions of the risk management cycle enables ongoing evaluation of outcomes in terms of both hazard and risk levels.

Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives

2020 ◽  
Vol 26 (28) ◽  
pp. 3468-3496
Author(s):  
Emilio Rodrigo ◽  
Marcio F. Chedid ◽  
David San Segundo ◽  
Juan C.R. San Millán ◽  
Marcos López-Hoyos
Keyword(s):  
Kidney Transplantation ◽  
Acute Rejection ◽  
Rescue Therapy ◽  
Standard Of Care ◽  
Rejection Rate ◽  
New Drugs ◽  
High Dose ◽  
Current Standard ◽  
Antibody Mediated Rejection ◽  
Cellular Rejection

: Although acute renal graft rejection rate has declined in the last years, and because an adequate therapy can improve graft outcome, its therapy remains as one of the most significant challenges for pharmacists and physicians taking care of transplant patients. Due to the lack of evidence highlighted by the available metaanalyses, we performed a narrative review focused on the basic mechanisms and current and future therapies of acute rejection in kidney transplantation. : According to Kidney Disease/Improving Global Outcomes (KDIGO) guidelines, both clinical and subclinical acute rejection episodes should be treated. Usually, high dose steroids and basal immunosuppression optimization are the first line of therapy in treating acute cellular rejection. Rabbit antithymocytic polyclonal globulins are used as rescue therapy for recurrent or steroid-resistant cellular rejection episodes. Current standard-of-care (SOC) therapy for acute antibody-mediated rejection (AbMR) is the combination of plasma exchange with intravenous immunoglobulin (IVIG). Since a significant rate of AbMR does not respond to SOC, different studies have analyzed the role of new drugs such as Rituximab, Bortezomib, Eculizumab and C1 inhibitors. Lack of randomized controlled trials and heterogenicity among performed studies limit obtaining definite conclusions. Data about new direct and indirect B cell and plasma cell depleting agents, proximal and terminal complement blockers, IL-6/IL-6R pathway inhibitors and antibody removal agents, among other promising drugs, are reviewed.

scholarly journals Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 864
Author(s):  
Christopher L. Cioffi
Keyword(s):  
Spinal Cord ◽  
Dorsal Horn ◽  
Therapeutic Potential ◽  
Opioid Analgesic ◽  
Critical Role ◽  
Analgesic Efficacy ◽  
Standard Of Care ◽  
Current Standard ◽  
Glycine Transporters ◽  
Pathological Pain

Among the myriad of cellular and molecular processes identified as contributing to pathological pain, disinhibition of spinal cord nociceptive signaling to higher cortical centers plays a critical role. Importantly, evidence suggests that impaired glycinergic neurotransmission develops in the dorsal horn of the spinal cord in inflammatory and neuropathic pain models and is a key maladaptive mechanism causing mechanical hyperalgesia and allodynia. Thus, it has been hypothesized that pharmacological agents capable of augmenting glycinergic tone within the dorsal horn may be able to blunt or block aberrant nociceptor signaling to the brain and serve as a novel class of analgesics for various pathological pain states. Indeed, drugs that enhance dysfunctional glycinergic transmission, and in particular inhibitors of the glycine transporters (GlyT1 and GlyT2), are generating widespread interest as a potential class of novel analgesics. The GlyTs are Na+/Cl−-dependent transporters of the solute carrier 6 (SLC6) family and it has been proposed that the inhibition of them presents a possible mechanism by which to increase spinal extracellular glycine concentrations and enhance GlyR-mediated inhibitory neurotransmission in the dorsal horn. Various inhibitors of both GlyT1 and GlyT2 have demonstrated broad analgesic efficacy in several preclinical models of acute and chronic pain, providing promise for the approach to deliver a first-in-class non-opioid analgesic with a mechanism of action differentiated from current standard of care. This review will highlight the therapeutic potential of GlyT inhibitors as a novel class of analgesics, present recent advances reported for the field, and discuss the key challenges associated with the development of a GlyT inhibitor into a safe and effective agent to treat pain.

scholarly journals Updated Insights on EGFR Signaling Pathways in Glioma

2021 ◽  
Vol 22 (2) ◽  
pp. 587
Author(s):  
Alexandru Oprita ◽  
Stefania-Carina Baloi ◽  
Georgiana-Adeline Staicu ◽  
Oana Alexandru ◽  
Daniela Elise Tache ◽  
...  
Keyword(s):  
Signaling Pathways ◽  
Treatment Strategies ◽  
Growth Factor Receptor ◽  
Standard Of Care ◽  
Egfr Signaling ◽  
Current Standard ◽  
Egfr Amplification ◽  
Epidermal Growth ◽  
New Diagnosis ◽  
Clear Clinical Benefit

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma is better understood. For the newly diagnosed, the current standard of care is represented by resection followed by radiotherapy and temozolomide administration, but because median overall survival remains poor, new diagnosis and treatment strategies are needed. Due to the quick progression, even with aggressive multimodal treatment, glioblastoma remains almost incurable. It is known that epidermal growth factor receptor (EGFR) amplification is a characteristic of the classical subtype of glioma. However, targeted therapies against this type of receptor have not yet shown a clear clinical benefit. Many factors contribute to resistance, such as ineffective blood–brain barrier penetration, heterogeneity, mutations, as well as compensatory signaling pathways. A better understanding of the EGFR signaling network, and its interrelations with other pathways, are essential to clarify the mechanisms of resistance and create better therapeutic agents.

A comparison between 25-gauge and 22-gauge Franseen needles for endoscopic ultrasound-guided sampling of pancreatic and peripancreatic masses: a randomized non-inferiority study

Endoscopy ◽  
2021 ◽  
Author(s):  
Dongwook Oh ◽  
Joonseog Kong ◽  
Sung Woo Ko ◽  
Seung-Mo Hong ◽  
Hoonsub So ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Endoscopic Ultrasound ◽  
Care Center ◽  
Tertiary Care ◽  
Standard Of Care ◽  
Fine Needle Biopsy ◽  
Needle Aspiration ◽  
Adverse Event Rate ◽  
Current Standard ◽  
Fine Needle

Abstract Background Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) and fine-needle biopsy (FNB) are the current standard of care for sampling pancreatic and peripancreatic masses. Recently, a 22G EUS-FNB needle with Franseen geometry was developed, and this device was also introduced in a 25G platform. We compared the performance of the 25G and 22G Franseen needles for EUS-guided sampling of pancreatic and peripancreatic solid masses. Methods We conducted a parallel-group randomized non-inferiority trial at a tertiary-care center from November 2018 to May 2019. The primary outcome was the quality of the histologic core assessed using the Gerke score. The optimal histologic core is indicated by a Gerke score of 4 or 5, which enables optimal histologic interpretation. The overall diagnostic accuracy and adverse event rate were also evaluated. Results 140 patients were enrolled and randomized (1:1) to the 25G and 22G groups. Tissue acquisition by EUS-FNB was successful in all patients. The optimal histologic core procurement rate was 87.1 % (61/70) for the 25G needle vs. 97.1 % (68/70) for the 22G; difference −10 % (95 % confidence interval −17.35 % to −2.65 %). High quality specimens were more frequently obtained in the 22G group than in the 25G group (70.0 % [49/70] vs. 28.6 % [20 /70], respectively; P < 0.001). The overall diagnostic accuracy did not differ between the groups (97.4 % for 25G vs. 100 % for 22G). Conclusions The 25G Franseen needle was inferior to the 22G needle in histologic core procurement. Therefore, for cases in which tissue architecture is pivotal for diagnosis, a 22G needle, which procures relatively higher quality specimens than the 25G needle, should be used.

scholarly journals Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma

2021 ◽  
Vol 14 (1) ◽  
pp. 51
Author(s):  
Brinda Balasubramanian ◽  
Simran Venkatraman ◽  
Kyaw Zwar Myint ◽  
Tavan Janvilisri ◽  
Kanokpan Wongprasert ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
Drug Development ◽  
Surgical Resection ◽  
Treatment Options ◽  
Standard Of Care ◽  
Time Data ◽  
Current Standard ◽  
Innovative Drug ◽  
Curative Intent

Cholangiocarcinoma (CCA), a group of malignancies that originate from the biliary tract, is associated with a high mortality rate and a concerning increase in worldwide incidence. In Thailand, where the incidence of CCA is the highest, the socioeconomic burden is severe. Yet, treatment options are limited, with surgical resection being the only form of treatment with curative intent. The current standard-of-care remains adjuvant and palliative chemotherapy which is ineffective in most patients. The overall survival rate is dismal, even after surgical resection and the tumor heterogeneity further complicates treatment. Together, this makes CCA a significant burden in Southeast Asia. For effective management of CCA, treatment must be tailored to each patient, individually, for which an assortment of targeted therapies must be available. Despite the increasing numbers of clinical studies in CCA, targeted therapy drugs rarely get approved for clinical use. In this review, we discuss the shortcomings of the conventional clinical trial process and propose the implementation of a novel concept, co-clinical trials to expedite drug development for CCA patients. In co-clinical trials, the preclinical studies and clinical trials are conducted simultaneously, thus enabling real-time data integration to accurately stratify and customize treatment for patients, individually. Hence, co-clinical trials are expected to improve the outcomes of clinical trials and consequently, encourage the approval of targeted therapy drugs. The increased availability of targeted therapy drugs for treatment is expected to facilitate the application of precision medicine in CCA.

Sign in / Sign up

Export Citation Format

Share Document